The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
because in that trial the relative risk reduction if you compare pcsk9 with placebo was only 15 percent so people were kind of expecting like a 20 plus percent reduction and many people were kind of disappointed by by that but i mean it happened over 2.2 years only so that's what's underrepresented
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.